By Edward Winnick

NEW YORK (GenomeWeb News) - Fluidigm officials said Monday that the firm is focusing on growing its business and inking partnerships as it keeps its eye on a potential initial public offering.

The microfluidics and array manufacturer was forced to withdraw its proposed IPO amid the market meltdown a year ago. At the time, company officials said that Fluidigm would go public once the markets stabilized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.